-
1
-
-
0029859584
-
Con: Heparin is not the best anticoagulant for cardiopulmonary bypass
-
Fitch JCK. Con: heparin is not the best anticoagulant for cardiopulmonary bypass. J Cardiothor Vasc Anesth 1996;10:819-21.
-
(1996)
J Cardiothor Vasc Anesth
, vol.10
, pp. 819-821
-
-
Fitch, J.C.K.1
-
2
-
-
0030551051
-
Hemorrhage and the use of blood products after adult cardiac operations: Myths and realities
-
Bélisle S, Hardy JF. Hemorrhage and the use of blood products after adult cardiac operations: myths and realities. Ann Thorac Surg 1996;62:1908-17.
-
(1996)
Ann Thorac Surg
, vol.62
, pp. 1908-1917
-
-
Bélisle, S.1
Hardy, J.F.2
-
3
-
-
0032942850
-
Cardiac bypass haemostasis: Putting blood through the mill
-
Bevan DH. Cardiac bypass haemostasis: putting blood through the mill. Br J Haematol 1999;104:208-19.
-
(1999)
Br J Haematol
, vol.104
, pp. 208-219
-
-
Bevan, D.H.1
-
4
-
-
0030540964
-
Reduction in requirements for allogeneic blood products: Nonpharmacologic methods
-
Hardy JF, Bélisle S, Janvier G, Samama CM. Reduction in requirements for allogeneic blood products: nonpharmacologic methods. Ann Thorac Surg 1996;62:1935-43.
-
(1996)
Ann Thorac Surg
, vol.62
, pp. 1935-1943
-
-
Hardy, J.F.1
Bélisle, S.2
Janvier, G.3
Samama, C.M.4
-
5
-
-
0029792102
-
Haemostatic changes in the pulmonary blood during cardiopulmonary bypass
-
Cardigan RA, Hamilton-Davies C, McDonald S, Purdy G, Mackie IJ, Webb AR, et al. Haemostatic changes in the pulmonary blood during cardiopulmonary bypass. Blood Coagul Fibrinolysis 1996;7:567-77.
-
(1996)
Blood Coagul Fibrinolysis
, vol.7
, pp. 567-577
-
-
Cardigan, R.A.1
Hamilton-Davies, C.2
McDonald, S.3
Purdy, G.4
Mackie, I.J.5
Webb, A.R.6
-
6
-
-
0034529253
-
Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis
-
Follis F, Schmidt CA. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis. Ann Thorac Surg 2000;70:2173-81.
-
(2000)
Ann Thorac Surg
, vol.70
, pp. 2173-2181
-
-
Follis, F.1
Schmidt, C.A.2
-
7
-
-
18744411773
-
Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuit
-
Fung M, Loubser PG, Undar A, Mueller M, Sun C, Sun WN, et al. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuit. J Thorac Cardiovasc Surg 2001;122:113-22.
-
(2001)
J Thorac Cardiovasc Surg
, vol.122
, pp. 113-122
-
-
Fung, M.1
Loubser, P.G.2
Undar, A.3
Mueller, M.4
Sun, C.5
Sun, W.N.6
-
8
-
-
0036159916
-
Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery
-
Lemmer JH, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002;123:213-7.
-
(2002)
J Thorac Cardiovasc Surg
, vol.123
, pp. 213-217
-
-
Lemmer, J.H.1
Despotis, G.J.2
-
9
-
-
0037804799
-
Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass
-
Chandler WL, Velan T. Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass. Blood 2003;101:4355-62.
-
(2003)
Blood
, vol.101
, pp. 4355-4362
-
-
Chandler, W.L.1
Velan, T.2
-
10
-
-
0035125405
-
Heparin and low-molecular-weight heparin: Mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
-
Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-107S.
-
(2001)
Chest
, vol.119
-
-
Hirsh, J.1
Warkentin, T.E.2
Shaughnessy, S.G.3
Anand, S.S.4
Halperin, J.L.5
Raschke, R.6
-
11
-
-
0028809946
-
Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass
-
Khuri S, Valeri R, Loscalzo J, Weinstein MJ, Birjiniuk V, Healy NA, et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995;60:1008-14.
-
(1995)
Ann Thorac Surg
, vol.60
, pp. 1008-1014
-
-
Khuri, S.1
Valeri, R.2
Loscalzo, J.3
Weinstein, M.J.4
Birjiniuk, V.5
Healy, N.A.6
-
12
-
-
0034006462
-
Altered plasma antigen levels of tissue factor pathway inhibitor during open-heart surgery
-
Sun LB, Utoh J, Kunitomo R, Tsurusaki S, Tagami H, Hirata T, et al. Altered plasma antigen levels of tissue factor pathway inhibitor during open-heart surgery. Surg Today 2000;30:122-6.
-
(2000)
Surg Today
, vol.30
, pp. 122-126
-
-
Sun, L.B.1
Utoh, J.2
Kunitomo, R.3
Tsurusaki, S.4
Tagami, H.5
Hirata, T.6
-
13
-
-
0035116825
-
Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: Role of tissue factor pathway inhibitor
-
Kojima T, Gando S, Kemmotsu O, Mashio H, Goda Y, Kawahigashi H, et al. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor. J Cardiothorac Vasc Anesth 2001;15:60-4.
-
(2001)
J Cardiothorac Vasc Anesth
, vol.15
, pp. 60-64
-
-
Kojima, T.1
Gando, S.2
Kemmotsu, O.3
Mashio, H.4
Goda, Y.5
Kawahigashi, H.6
-
14
-
-
84870858023
-
Cardiopulmonary bypass with a low-molecular-weight heparin fraction
-
Gouault-Heilmann M, Huet Y, Contant G, Payen D, Bloch G, Rapin M. Cardiopulmonary bypass with a low-molecular-weight heparin fraction. Lancet 1983;ii:1374.
-
(1983)
Lancet
-
-
Gouault-Heilmann, M.1
Huet, Y.2
Contant, G.3
Payen, D.4
Bloch, G.5
Rapin, M.6
-
15
-
-
0021220935
-
Low-molecular-weight heparin in extracorporeal circulation
-
Massonnet-Castel S, Pelissier E, Dreyfus G, et al. Low-molecular-weight heparin in extracorporeal circulation. Lancet 1984;i:1182-3.
-
(1984)
Lancet
-
-
Massonnet-Castel, S.1
Pelissier, E.2
Dreyfus, G.3
-
16
-
-
0026559574
-
Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia
-
Robitaille D, Leclerc JR, Laberge R, Sahab P, Atkinson S, Cartier R. Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia. J Thorac Cardiovasc Surg 1992;103:597-9.
-
(1992)
J Thorac Cardiovasc Surg
, vol.103
, pp. 597-599
-
-
Robitaille, D.1
Leclerc, J.R.2
Laberge, R.3
Sahab, P.4
Atkinson, S.5
Cartier, R.6
-
17
-
-
0028183129
-
Fragmin (LMWH) versus heparin for anticoagulation during in vitro recycling of human blood in cardiopulmonary bypass circuits: Dose-dependence and mechanisms of clotting
-
Bagge L, Holmer E, Wahlberg T, Nyström SO, Tydén H. Fragmin (LMWH) versus heparin for anticoagulation during in vitro recycling of human blood in cardiopulmonary bypass circuits: dose-dependence and mechanisms of clotting. Blood Coagul Fibrinolysis 1994;5:273-80.
-
(1994)
Blood Coagul Fibrinolysis
, vol.5
, pp. 273-280
-
-
Bagge, L.1
Holmer, E.2
Wahlberg, T.3
Nyström, S.O.4
Tydén, H.5
-
18
-
-
0001814792
-
Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia
-
Pifarré R, Ed. Philadelphia, PA: Hanley & Belfus Inc
-
Magnani HN, Beijering RJR, Ten Cate JW, Chong BH. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: Pifarré R, Ed. New anticoagulants for the cardiovascular patient. Philadelphia, PA: Hanley & Belfus Inc; 1997. p. 487-500.
-
(1997)
New Anticoagulants for the Cardiovascular Patient
, pp. 487-500
-
-
Magnani, H.N.1
Beijering, R.J.R.2
Ten Cate, J.W.3
Chong, B.H.4
-
19
-
-
0031680310
-
The clinical use and laboratory monitoring of low-molecular weight heparin, danaparoid, hirudin and related compounds, and argatroban: College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy
-
Laposata M, Green D, van Cott E, Barrowcliffe TW, Goodnight SH, Sosolik RC. The clinical use and laboratory monitoring of low-molecular weight heparin, danaparoid, hirudin and related compounds, and argatroban: College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy. Arch Pathol Lab Med 1998;122:799-807.
-
(1998)
Arch Pathol Lab Med
, vol.122
, pp. 799-807
-
-
Laposata, M.1
Green, D.2
Van Cott, E.3
Barrowcliffe, T.W.4
Goodnight, S.H.5
Sosolik, R.C.6
-
20
-
-
0025227931
-
Bleeding complications associated with cardiopulmonary bypass
-
Woodman RC, Harker L. Bleeding complications associated with cardiopulmonary bypass. Blood 1990;76:1680-97.
-
(1990)
Blood
, vol.76
, pp. 1680-1697
-
-
Woodman, R.C.1
Harker, L.2
-
21
-
-
0027249775
-
Thrombin generation during cardiac surgery: Is heparin the ideal anticoagulant?
-
Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? Thromb Haemost 1993;70:259-62.
-
(1993)
Thromb Haemost
, vol.70
, pp. 259-262
-
-
Brister, S.J.1
Ofosu, F.A.2
Buchanan, M.R.3
-
22
-
-
0027402688
-
Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo
-
Levi M, Roem D, Kamp AM, de Boer JP, Hack CE, Ten Cate JW. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemost 1993;69:141-6.
-
(1993)
Thromb Haemost
, vol.69
, pp. 141-146
-
-
Levi, M.1
Roem, D.2
Kamp, A.M.3
De Boer, J.P.4
Hack, C.E.5
Ten Cate, J.W.6
-
23
-
-
0016788423
-
The hemostatic mechanism after open-heart surgery. II. Frequency of abnormal platelet functions during and after extracorporeal circulation
-
McKenna R, Bachmann F, Wittaker B, Gilson J, Weinberg M. The hemostatic mechanism after open-heart surgery. II. Frequency of abnormal platelet functions during and after extracorporeal circulation. J Thorac Cardiovasc Surg 1975;70:298-308.
-
(1975)
J Thorac Cardiovasc Surg
, vol.70
, pp. 298-308
-
-
McKenna, R.1
Bachmann, F.2
Wittaker, B.3
Gilson, J.4
Weinberg, M.5
-
24
-
-
0019180607
-
Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective alpha-granule release
-
Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980;56:824-34.
-
(1980)
Blood
, vol.56
, pp. 824-834
-
-
Harker, L.A.1
Malpass, T.W.2
Branson, H.E.3
Hessel, E.A.4
Slichter, S.J.5
-
25
-
-
0034867946
-
Platelet function analyzer (PFA-100): A tool to quantify congenital or acquired platelet dysfunction
-
Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction (review article). J Lab Clin Med 2001;138:152-63.
-
(2001)
J Lab Clin Med
, vol.138
, pp. 152-163
-
-
Jilma, B.1
-
26
-
-
0033678065
-
A study of platelet functions with a new analyzer using high shear stress (PFA100TM) in patients undergoing coronary artery bypass graft
-
Lasne D, Fiemeyer A, Chatellier G, Chammas C, Baron JF, Aiach M. A study of platelet functions with a new analyzer using high shear stress (PFA100TM) in patients undergoing coronary artery bypass graft. Thromb Haemost 2000;84:794-9.
-
(2000)
Thromb Haemost
, vol.84
, pp. 794-799
-
-
Lasne, D.1
Fiemeyer, A.2
Chatellier, G.3
Chammas, C.4
Baron, J.F.5
Aiach, M.6
-
27
-
-
0242401773
-
Calibrated automated thrombin generation measurement in clotting plasma
-
Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003;33:4-15.
-
(2003)
Pathophysiol Haemost Thromb
, vol.33
, pp. 4-15
-
-
Hemker, H.C.1
Giesen, P.2
Al Dieri, R.3
Regnault, V.4
De Smedt, E.5
Wagenvoord, R.6
-
28
-
-
25344434433
-
The thrombin potential in contrast to clotting times is only slightly modified after uncomplicated heart valve replacement in adults
-
Carteaux JP, Regnault V, Lekehal M, Lecompte T. The thrombin potential in contrast to clotting times is only slightly modified after uncomplicated heart valve replacement in adults. J Thromb Haemost 2003;Suppl 1:P0595.
-
(2003)
J Thromb Haemost
, Issue.SUPPL. 1
-
-
Carteaux, J.P.1
Regnault, V.2
Lekehal, M.3
Lecompte, T.4
-
29
-
-
0033831036
-
Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery
-
Despotis GJ, Goodnough LT. Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery. Ann Thorac Surg 2000;70:S20-S32.
-
(2000)
Ann Thorac Surg
, vol.70
-
-
Despotis, G.J.1
Goodnough, L.T.2
-
30
-
-
0347812212
-
Point-of-care testing of hemostasis in cardiac surgery
-
Prisco D, Paniccia R. Point-of-care testing of hemostasis in cardiac surgery (review). Thromb J 2003;1:electronic version www.thrombosisjoumal.com.
-
(2003)
Thromb J
, pp. 1
-
-
Prisco, D.1
Paniccia, R.2
-
31
-
-
0032907242
-
Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery
-
Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999;88:312-9.
-
(1999)
Anesth Analg
, vol.88
, pp. 312-319
-
-
Shore-Lesserson, L.1
Manspeizer, H.E.2
DePerio, M.3
Francis, S.4
Vela-Cantos, F.5
Ergin, M.A.6
-
32
-
-
0034747516
-
Reproducibility and interchangeability of the thromboelastograph, Sonoclot and Hemochron activated coagulation time in cardiac surgery
-
Forestier F, Belisle S, Contant C, Harel F, Janvier G, Hardy JF. Reproducibility and interchangeability of the thromboelastograph, Sonoclot and Hemochron activated coagulation time in cardiac surgery. Can J Anaesth 2001;48:902-10.
-
(2001)
Can J Anaesth
, vol.48
, pp. 902-910
-
-
Forestier, F.1
Belisle, S.2
Contant, C.3
Harel, F.4
Janvier, G.5
Hardy, J.F.6
-
33
-
-
0031792073
-
Progress in point-of-care laboratory testing for assessing platelet function
-
Berkowitz S, Frelinger A, Hillman R. Progress in point-of-care laboratory testing for assessing platelet function. Am Heart J 1998;136:S51-S65.
-
(1998)
Am Heart J
, vol.136
-
-
Berkowitz, S.1
Frelinger, A.2
Hillman, R.3
-
35
-
-
0038554771
-
Whole blood coagulation thromboelastographic profiles employing minimal fissue factor activation
-
Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thromboelastographic profiles employing minimal fissue factor activation. J Thromb Haemost 2003;1:551-8.
-
(2003)
J Thromb Haemost
, vol.1
, pp. 551-558
-
-
Sorensen, B.1
Johansen, P.2
Christiansen, K.3
Woelke, M.4
Ingerslev, J.5
-
36
-
-
0037220690
-
The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery
-
Cammerer U, Dietrich W, Rampf T, Braun SL, Richter JA. The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anesth Analg 2003;96:51-7.
-
(2003)
Anesth Analg
, vol.96
, pp. 51-57
-
-
Cammerer, U.1
Dietrich, W.2
Rampf, T.3
Braun, S.L.4
Richter, J.A.5
-
38
-
-
0031415922
-
Drugs to minimize perioperative blood loss in cardiac surgery: Meta-analysis using perioperative blood transfusion as the outcome
-
Laupacis A, Fergusson D, for The International Study of Peri -operative Transfusion (ISPOT) Investigators. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analysis using perioperative blood transfusion as the outcome. Anesth Analg 1997;85:1258-67.
-
(1997)
Anesth Analg
, vol.85
, pp. 1258-1267
-
-
Laupacis, A.1
Fergusson, D.2
-
39
-
-
0026547135
-
Utilisation d'une prostacycline de synthèse en circulation extracorporelle
-
Massonnet-Castel S. Utilisation d'une prostacycline de synthèse en circulation extracorporelle. Presse Med 1992;21:113-8.
-
(1992)
Presse Med
, vol.21
, pp. 113-118
-
-
Massonnet-Castel, S.1
-
40
-
-
0027970684
-
Management of cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia using prostaglandin E1 and aspirin
-
Shorten GD, Comunale ME, Jonhson RG. Management of cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia using prostaglandin E1 and aspirin. J Cardiothor Vasc Anesth 1994;8:556-8.
-
(1994)
J Cardiothor Vasc Anesth
, vol.8
, pp. 556-558
-
-
Shorten, G.D.1
Comunale, M.E.2
Jonhson, R.G.3
-
41
-
-
0028836409
-
Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting
-
Speekenbrink RGH, Vonk ABA, Wildevuur CRH, Eijsman L. Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. Ann Thorac Surg 1995;59:438-42.
-
(1995)
Ann Thorac Surg
, vol.59
, pp. 438-442
-
-
Speekenbrink, R.G.H.1
Vonk, A.B.A.2
Wildevuur, C.R.H.3
Eijsman, L.4
-
42
-
-
0027515415
-
Ro 44-9883, a new nonpeptide glycoprotein IIb/IIIa antagonist, prevents platelet loss during experimental cardiopulmonary bypass
-
Carteaux JP, Roux S, Kuhn H, Tschopp T, Colombo V, Hadvary P. Ro 44-9883, a new nonpeptide glycoprotein IIb/IIIa antagonist, prevents platelet loss during experimental cardiopulmonary bypass. J Thor Cardiovasc Surg 1993;106:834-41.
-
(1993)
J Thor Cardiovasc Surg
, vol.106
, pp. 834-841
-
-
Carteaux, J.P.1
Roux, S.2
Kuhn, H.3
Tschopp, T.4
Colombo, V.5
Hadvary, P.6
-
43
-
-
0032785225
-
Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibit thrombin generation during cardiopulmonary bypass in baboons
-
Rao AK, Sun L, Hiramatsu Y, Gorman JH, Edmunds LH. Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibit thrombin generation during cardiopulmonary bypass in baboons. Thromb Haemost 1999;82:140-4.
-
(1999)
Thromb Haemost
, vol.82
, pp. 140-144
-
-
Rao, A.K.1
Sun, L.2
Hiramatsu, Y.3
Gorman, J.H.4
Edmunds, L.H.5
-
44
-
-
0035113150
-
Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia
-
Aouifi A, Blanc P, Piriou V, Bastien OH, French P, Hanss M, et al. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia. Ann Thorac Surg 2001;71:678-83.
-
(2001)
Ann Thorac Surg
, vol.71
, pp. 678-683
-
-
Aouifi, A.1
Blanc, P.2
Piriou, V.3
Bastien, O.H.4
French, P.5
Hanss, M.6
-
45
-
-
0034535540
-
Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia type II and impaired renal function using heparin and the platelet GPIIb/IIIa inhibitor tirofiban as anticoagulant
-
Koster A, Loebe M, Mertzlufft F, Kuppe H, Hetzer R. Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia type II and impaired renal function using heparin and the platelet GPIIb/ IIIa inhibitor tirofiban as anticoagulant. Ann Thorac Surg 2000;70:2160-1.
-
(2000)
Ann Thorac Surg
, vol.70
, pp. 2160-2161
-
-
Koster, A.1
Loebe, M.2
Mertzlufft, F.3
Kuppe, H.4
Hetzer, R.5
-
46
-
-
0035141342
-
Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glyocprotein IIb-IIIa antagonist tirofiban
-
Koster A, Kukucka M, Bach F, Meyer O, Fischer T, Mertzlufft F, et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glyocprotein IIb-IIIa antagonist tirofiban. Anesthesiology 2001;94:245-51.
-
(2001)
Anesthesiology
, vol.94
, pp. 245-251
-
-
Koster, A.1
Kukucka, M.2
Bach, F.3
Meyer, O.4
Fischer, T.5
Mertzlufft, F.6
-
47
-
-
0028812558
-
Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass
-
Ovrum E, Brosstad F, Holen EA, Tangen G, Abdelnoor M. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass. Circulation 1995;92:2579-84.
-
(1995)
Circulation
, vol.92
, pp. 2579-2584
-
-
Ovrum, E.1
Brosstad, F.2
Holen, E.A.3
Tangen, G.4
Abdelnoor, M.5
-
48
-
-
0036090385
-
Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits
-
Aldea G. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J Thorac Cardiovasc Surg 2002;123:742-55.
-
(2002)
J Thorac Cardiovasc Surg
, vol.123
, pp. 742-755
-
-
Aldea, G.1
-
49
-
-
0031725667
-
A heparin-coated circuit maintains platelet aggregability in response to shear stress in an in vitro model of cardiopulmonary bypass
-
Hioki I, Nishikawa M, Onoda K, Shimono T, Shimpo H, Tanaka K, et al. A heparin-coated circuit maintains platelet aggregability in response to shear stress in an in vitro model of cardiopulmonary bypass. Thromb Haemost 1998;80:437-42.
-
(1998)
Thromb Haemost
, vol.80
, pp. 437-442
-
-
Hioki, I.1
Nishikawa, M.2
Onoda, K.3
Shimono, T.4
Shimpo, H.5
Tanaka, K.6
-
50
-
-
0035128439
-
New anticoagulant drugs
-
Weitz J, Hirsh J. New anticoagulant drugs. Chest 2001;119:S95-S107.
-
(2001)
Chest
, vol.119
-
-
Weitz, J.1
Hirsh, J.2
-
51
-
-
0031965512
-
Heparinless cardiopulmonary bypass with active-site blocked factor IXa: A preliminary study on the dog
-
Spanier TB, Oz MC, Minanov OP, Simantov R, Kisiel W, Stern DM, et al. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. J Thorac Cardiovasc Surg 1998;115:1179-88.
-
(1998)
J Thorac Cardiovasc Surg
, vol.115
, pp. 1179-1188
-
-
Spanier, T.B.1
Oz, M.C.2
Minanov, O.P.3
Simantov, R.4
Kisiel, W.5
Stern, D.M.6
-
52
-
-
0030755896
-
Direct thrombin inhibitors: Appraisal of the antithrombotic/hemorrhagic balance
-
Verstraete M. Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance. Thromb Haemost 1997;78:357-63.
-
(1997)
Thromb Haemost
, vol.78
, pp. 357-363
-
-
Verstraete, M.1
-
53
-
-
0026102517
-
Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model
-
Walenga JM, Bakhos M, Messmore HL, Koza MJ, Wallock M, Orfei E, et al. Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model. Blood Coag Fibrinolysis 1991;2:105-11.
-
(1991)
Blood Coag Fibrinolysis
, vol.2
, pp. 105-111
-
-
Walenga, J.M.1
Bakhos, M.2
Messmore, H.L.3
Koza, M.J.4
Wallock, M.5
Orfei, E.6
-
54
-
-
0026016634
-
Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model
-
Walenga JM, Bakhos M, Messmore HL, Fareed J, Pifarre R. Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model. Ann Thorac Surg 1991;51:271-7.
-
(1991)
Ann Thorac Surg
, vol.51
, pp. 271-277
-
-
Walenga, J.M.1
Bakhos, M.2
Messmore, H.L.3
Fareed, J.4
Pifarre, R.5
-
55
-
-
0032956980
-
Acute pulmonary hypertension after cardiopulmonary bypass in pig: The role of endogenous endothelin
-
Carteaux JP, Roux S, Siaghy M, Schjöth B, Dolofon P, Bechamps Y, et al. Acute pulmonary hypertension after cardiopulmonary bypass in pig: the role of endogenous endothelin. Eur J Cardiothorac Surg 1999;15:346-52.
-
(1999)
Eur J Cardiothorac Surg
, vol.15
, pp. 346-352
-
-
Carteaux, J.P.1
Roux, S.2
Siaghy, M.3
Schjöth, B.4
Dolofon, P.5
Bechamps, Y.6
-
56
-
-
0001912062
-
Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia
-
Warkentin TE, Greinacher A, Eds. New York: Marcel Dekker, Inc
-
Pötzsch B, Madlener K. Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, Eds. Heparin-induced thrombocytopenia. New York: Marcel Dekker, Inc; 2001. p. 429-44.
-
(2001)
Heparin-induced Thrombocytopenia
, pp. 429-444
-
-
Pötzsch, B.1
Madlener, K.2
-
57
-
-
0028952989
-
Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis
-
Carteaux JP, Gast A, Tschopp TB, Roux S. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circulation 1995;91:1568-74.
-
(1995)
Circulation
, vol.91
, pp. 1568-1574
-
-
Carteaux, J.P.1
Gast, A.2
Tschopp, T.B.3
Roux, S.4
-
58
-
-
0029045381
-
Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man
-
Riess FC, Lower C, Seelig C, Bleese N, Kormann J, Müller-Berghaus G, et al. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. J Thorac Cardiovasc Surg 1995;110:265-7.
-
(1995)
J Thorac Cardiovasc Surg
, vol.110
, pp. 265-267
-
-
Riess, F.C.1
Lower, C.2
Seelig, C.3
Bleese, N.4
Kormann, J.5
Müller-Berghaus, G.6
-
59
-
-
0031719763
-
Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin
-
Koster A, Kuppe H, Hetzer R, Sodian R, Crystal GJ, Mertzlufft F. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology 1998;89:777-80.
-
(1998)
Anesthesiology
, vol.89
, pp. 777-780
-
-
Koster, A.1
Kuppe, H.2
Hetzer, R.3
Sodian, R.4
Crystal, G.J.5
Mertzlufft, F.6
-
60
-
-
0034029876
-
Anticoagulation in extracorporeal circulation using recombinant hirudin: A case report
-
Behloz S, Grubitzsch H, Bergmann B, Wollert HG, Eckel L. Anticoagulation in extracorporeal circulation using recombinant hirudin: a case report. Perfusion 2000;15:257-60.
-
(2000)
Perfusion
, vol.15
, pp. 257-260
-
-
Behloz, S.1
Grubitzsch, H.2
Bergmann, B.3
Wollert, H.G.4
Eckel, L.5
-
61
-
-
0033975746
-
Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass
-
Latham P, Revelis AF, Joshi GP, DiMaio JM, Jessen ME. Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass. Anesthesiology 2000;92:263-6.
-
(2000)
Anesthesiology
, vol.92
, pp. 263-266
-
-
Latham, P.1
Revelis, A.F.2
Joshi, G.P.3
DiMaio, J.M.4
Jessen, M.E.5
-
62
-
-
1842295156
-
Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - Assessment of the whole blood ecarin clotting time
-
Pötzsch B, Madlener K, Seelig C, Riess FC, Greinacher A, Müller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - assessment of the whole blood ecarin clotting time. Thromb Haemost 1997;77:920-5.
-
(1997)
Thromb Haemost
, vol.77
, pp. 920-925
-
-
Pötzsch, B.1
Madlener, K.2
Seelig, C.3
Riess, F.C.4
Greinacher, A.5
Müller-Berghaus, G.6
-
63
-
-
0033961010
-
Hirudin as anticoagulant for cardiopulmonary bypass: Importance of preoperative renal function
-
Koster A, Pasic M, Bauer M, Kuppe H, Hetzer R. Hirudin as anticoagulant for cardiopulmonary bypass: importance of preoperative renal function. Ann Thorac Surg 2000;69:37-41.
-
(2000)
Ann Thorac Surg
, vol.69
, pp. 37-41
-
-
Koster, A.1
Pasic, M.2
Bauer, M.3
Kuppe, H.4
Hetzer, R.5
-
64
-
-
0033527370
-
Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin
-
Song X, Huhle G, Wang L, Hoffmann U, Harenberg J. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 1999;100:1528-32.
-
(1999)
Circulation
, vol.100
, pp. 1528-1532
-
-
Song, X.1
Huhle, G.2
Wang, L.3
Hoffmann, U.4
Harenberg, J.5
-
65
-
-
0033773210
-
Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia
-
Longrois D, de Maistre E, Bischoff N, Dopff C, Meistelman C, Angioï M, et al. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia (clinical report). Can J Anesth 2000;47:255-60.
-
(2000)
Can J Anesth
, vol.47
, pp. 255-260
-
-
Longrois, D.1
De Maistre, E.2
Bischoff, N.3
Dopff, C.4
Meistelman, C.5
Angioï, M.6
-
66
-
-
0022507422
-
Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery
-
George JN. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986;78:340-8.
-
(1986)
J Clin Invest
, vol.78
, pp. 340-348
-
-
George, J.N.1
-
67
-
-
0036587134
-
Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass
-
De Somer F. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2002;123:951-8.
-
(2002)
J Thorac Cardiovasc Surg
, vol.123
, pp. 951-958
-
-
De Somer, F.1
-
68
-
-
0034680004
-
Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia
-
Pötzsch B, Klövekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000;343:515.
-
(2000)
N Engl J Med
, vol.343
, pp. 515
-
-
Pötzsch, B.1
Klövekorn, W.P.2
Madlener, K.3
-
69
-
-
0029825538
-
Utilisation de l'Orgaran pour une circulation extracorporelle chez une patiente allergique à l'héparine
-
Bretelle C, Leude E, Quilici J, Vaillant A. Utilisation de l'Orgaran pour une circulation extracorporelle chez une patiente allergique à l'héparine. Presse Med 1996;25:1846-7.
-
(1996)
Presse Med
, vol.25
, pp. 1846-1847
-
-
Bretelle, C.1
Leude, E.2
Quilici, J.3
Vaillant, A.4
|